Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

▪ Background/Introduction: Lower-risk (IPSS low risk and Int-1) myelodysplastic syndromes (MDS) are typically treated supportively to address cytopenias. DNA methyltransferase inhibitors (DNMTi) such as azacitidine and decitabine (DEC) are FDA-approved for higher risk MDS patients (pts), and while t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.66-66
Hauptverfasser:	Garcia-Manero, Guillermo, McCloskey, James K, Griffiths, Elizabeth A., Yee, Karen, Zeidan, Amer M., Al-Kali, Aref, Deeg, H. Joachim, Patel, Prapti, Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat Y., Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Savona, Michael R.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!